Meribank Biotech Co., Ltd (TPEX:4724)

Taiwan · Delayed Price · Currency is TWD

12.10

-0.35 (-2.81%)

May 29, 2026, 1:37 PM CST

Revenue by Segment

Financials in millions TWD. Fiscal year is January - December.

Millions TWD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017	Dec '16 Dec 31, 2016
Management Consulting Department	159.76M	88.24M	-	-	-
Management Consulting Department Growth	81.04%	-	-	-	-
Other	65.85M	50.16M	26.90M	17.04M	-
Other Growth	31.29%	86.43%	57.93%	-	-
Stem Cell Department	246.16M	228.03M	207.44M	163.09M	163.08M
Stem Cell Department Growth	7.95%	9.93%	27.20%	0.01%	-16.11%
Total	471.76M	366.43M	234.34M	180.12M	163.08M
Total Growth	28.75%	56.37%	30.10%	10.45%	-16.11%

Revenue by Geography

Financials in millions TWD. Fiscal year is January - December.

Millions TWD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017	Dec '16 Dec 31, 2016
Taiwan	471.76M	366.43M	234.34M	180.12M	163.08M
Taiwan Growth	28.75%	56.37%	30.10%	10.45%	-16.11%
Total	471.76M	366.43M	234.34M	180.12M	163.08M
Total Growth	28.75%	56.37%	30.10%	10.45%	-16.11%

Source: S&P Global Market Intelligence.